Recently listed clinical-stage pharmaceutical company; specific pipeline and disease focus not confidently known.
Recently listed clinical-stage pharmaceutical company; specific pipeline and disease focus not confidently known.
Moat: none
Employees: 106
Size Definium Therapeutics (DFTX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $3.99B, the 1342nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $29.12 on 18 Nov 2026.
Performance Over six months the shares gained 39.5%, against +0.8% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 20 in its peer set.
Short interest Short interest is 7.2% of the free float (30 Oct 2026).
Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | $0 | $0 | -$527,000 | -$3.16M | -$3.22M |
| EBITDA | -$254M | -$166M | -$103M | -$90.7M | -$63.1M |
| Net income | -$337M | -$184M | -$109M | -$95.7M | -$56.8M |
| Free cash flow | -$189M | -$132M | -$79.1M | -$64.4M | -$50.1M |
| Capital expenditure | $0 | $0 | $0 | $0 | $0 |
| Total debt | $36.7M | $40.6M | $21.9M | $14.1M | $72,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | DFTX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -17.0% | +2.6% | 3rd lowest of 21 |
| 6-month return | +39.5% | +0.8% | 2nd highest of 20 |
| Distance from 52-week high | -41.4% | -23.4% | 5th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Definium Therapeutics DFTX | United States | $3.99B | +40% | n/a | n/a | n/a | n/a | n/a |
| HanmiPharm 128940.KS | South Korea | $3.95B | -2% | +14% | 16% | 3.3× | 4.7% | +7.5% |
| Novast Laboratories 301569.SZ | China | $3.92B | n/a | +3% | 27% | 27.6× | 57.4% | +3.1% |
| Yuhan 000100.KS | South Korea | $4.11B | -10% | +8% | 6% | 2.3× | n/a | n/a |
| Santen Pharmaceutical 4536.T | Japan | $4.14B | +10% | +2% | 16% | 2.0× | -5.0% | +3.2% |
| Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS | China | $3.81B | -38% | +227% | 74% | 5.5× | 0.9% | +45.1% |
| Livzon Pharmaceutical 000513.SZ | China | $3.76B | +4% | -14% | 19% | 2.3× | -9.6% | +2.7% |
| Tianjin Pharmaceutical Da Ren Tang 600329.SS | China | $3.75B | -10% | -13% | 20% | 5.1× | 16.2% | -5.8% |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.75B | +12% | +14% | 20% | 4.2× | 1.2% | +12.1% |
| Tarsus Pharmaceuticals TARS | United States | $3.74B | +17% | +86% | -10% | 5.2× | 34.7% | +159.5% |
| Xenon Pharmaceuticals XENE | United States | $3.71B | -31% | -100% | n/a | n/a | n/a | n/a |
| Shenzhen Salubris Pharmaceuticals 002294.SZ | China | $4.31B | -24% | +14% | 11% | 5.8× | 12.4% | +9.7% |
| SELLAS Life Sciences SLS | United States | $3.66B | +100% | n/a | n/a | n/a | n/a | n/a |
| Organon & OGN | United States | $3.66B | +3% | -3% | 20% | 1.8× | -4.1% | -1.0% |
| Camurus CAMX.ST | Sweden | $4.36B | +36% | +3% | 38% | 16.6× | 7.9% | +46.5% |
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.36B | +12% | -4% | 32% | 3.2× | -9.9% | +0.3% |
| Ajanta Pharma AJANTPHARM.NS | India | $4.38B | +1% | +25% | 25% | 6.5× | 23.8% | +13.8% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.61B | 0% | +10% | 12% | 3.2× | 6.4% | +5.9% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.60B | -7% | +8% | 4% | 0.6× | -4.9% | +7.8% |
| Guangzhou Baiyunshan Pharmaceutical 600332.SS | China | $4.45B | -13% | +1% | 3% | 0.6× | -0.7% | +4.7% |
| Wockhardt WOCKPHARMA.NS | India | $3.52B | +25% | +26% | 13% | 9.3× | 58.0% | +4.2% |